B O O K - American College of Rheumatology

ACR Poster Session A
559. Week 12 Response Is a Better Predictor Than Baseline
Disease Characteristics of Long-Term Remission in Ankylosing
Spondylitis. Joachim Sieper 3 , Desiree van der Heijde 4 ,
Steve Brown 2 , Frederic Lavie 1 and Aileen Pangan 2 , 1 Abbott
Laboratories, Rungis, France, 2 Abbott Laboratories, Abbott Park,
IL, 3 Charité Universitätsmedizin Berlin, Berlin, Germany, 4 Leiden
University Medical Center, Leiden, The Netherlands.
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical
Aspects and Therapeutics I
560. A Multi-Center, Open-Label, Proof of Concept Study of
Imatinib Mesylate Demonstrates No Benefit for the Treatment
of Fibrosis in Patients with Early, Diffuse Systemic Sclerosis.
Oliver Distler 8 , Jorg H. W. Distler 9 , John Varga 4 , Christopher
P. Denton 7 , Robert A. Lafyatis 1 , Fredrick M. Wigley 3 , Georg
Schett 2 , Marco Matucci-Cerinic 10 , Timothy M. Wright 5 , Arthur
P. Bertolino 6 and Peter Gergely, Jr 6 , 1 Boston University School
of Medicine, Arlington, MA, 2 Friedrich Alexander Univ,
Erlangen, Germany, 3 Johns Hopkins University, Baltimore, MD,
4
Northwestern Univ Feinberg School, Chicago, IL, 5 Novartis
Institutes for Biomedical Research, Cambridge, MA, 6 Novartis
Institutes for Biomedical Research, 7 Royal Free Hospital,
London, United Kingdom, 8 University Hospital Zurich, Zurich,
Switzerland, 9 University of Erlangen, Erlangen, Germany,
10
University of Florence, Firenze, Italy.
561. Baseline Differences in the “Borderline” Pulmonary
Hypertension vs. “Normal” Hemodynamics: PHAROS Registry.
Dinesh Khanna 4 , Rajeev Saggar 4 , Daniel Furst 4 , Lorinda Chung 3 ,
James Seibold 5 , Tracy Frech 7 , ELENA Schiopu 6 , Rajan Saggar 4 ,
Marcy Bolster 2 , Virginia Steen 1 and PHAROS Investigators,
1
Georgetown University, 2 MUSC, 3 Stanford, 4 UCLA, 5 Univ of
Connecticut, 6 Univ of Michigan, 7 Univ of Utah.
562. Cigarette Smoking Is Not a Risk Factor for Systemic Sclerosis.
Prateek Chaudhary 3 , Xing Chen 6 , Shervin Assassi 3 , Olga Gorlova 7 ,
Hilda Draeger 5 , Emilio Gonzalez 8 , Terry McNearney 1 , Marilyn
Perry 3 , Jason Anderson 4 and Maureen D. Mayes 2 , 1 Indianapolis,
IN, 2 University of Texas Health Science Center at Houston,
Houston, TX, 3 University of Texas Health Science Center
Houston, Houston, TX, 4 University of Texas Health Science
Center Houston, 5 University of Texas Health Science Center San
Antonio, San Antonio, TX, 6 University of Texas MD Anderson
Cancer Center, Houston, TX, 7 University of Texas MD Anderson
Health Science Center, Houston, TX, 8 University of Texas Medical
Branch at Galveston, Galveston, TX.
563. Clinical Characteristics of Systemic Sclerosis Sine Scleroderma
Associated Interstitial Lung Disease. Rohit Aggarwal 3 , Mary
Lucas 2 , Noreen Fertig 2 and Thomas A. Medsger 1 , 1 Univ of
Pittsburgh, Pittsburgh, PA, 2 University of Pittsburgh, 3 University
of Pittsburgh Medical Center, Pittsburgh, PA.
564. Clinical Predictive Factors on Response to Oral Monotherapy in
Patients with Systemic Sclerosis-Associated Pulmonary Arterial
Hypertension. Yih Chang Lin, Soumya Chatterjee, Meng Xu,
Raed Dweik and Joseph Parambil, Cleveland Clinic.
565. Combined Analysis of Outcomes of Sitaxentan Treatment
of Pulmonary Arterial Hypertension (PAH) Associated with
Systemic Sclerosis (Scleroderma). James R. Seibold 5 , Marco
Matucci-Cerinic 6 , Michael Louie 3 , Stephen Watt 3 , Simon A. Teal 4 ,
Xuexuan Liu 1 , Lie-Ju Hwang 3 and David Langleben 2 , 1 Aerotek,
Houston, TX, 2 Cardiology, Montreal Jewish Hospital, Montreal,
Canada, 3 Pfizer Inc, New York, NY, 4 Pfizer Ltd, Tadworth, Surrey,
UK, 5 Rheumatology, University of Connecticut, Farmington,
Farmington, CT, 6 University of Florence, Firenze, Italy.
566. Comparative Analysis of Change in Modified Rodnan Skin
Score in Patients with Diffuse Systemic Sclerosis Receiving
Imatinib Mesylate Suggests Similar Disease Course to Matched
Patients Receiving Standard Therapy. Christopher P. Denton 9 ,
Svetlana I. Nihtyanova 2 , John Varga 5 , Oliver Distler 10 , Fredrick M.
Wigley 4 , Robert A. Lafyatis 1 , Jorg H. W. Distler 11 , Georg Schett 3 ,
Marco Matucci-Cerinic 12 , Timothy M. Wright 6 , Monica Costa
Antunes 8 , Amy Racine 8 , Arthur P. Bertolino 7 and Peter Gergely,
Jr 7 , 1 Boston University School of Medicine, Arlington, MA,
2
Center for Rheumatology and Connective Tissue Diseases, UCL
Medical School, London, United Kingdom, 3 Friedrich Alexander
Univ, Erlangen, Germany, 4 Johns Hopkins University, Baltimore,
MD, 5 Northwestern Univ Feinberg School, Chicago, IL, 6 Novartis
Institutes for Biomedical Research, Cambridge, MA, 7 Novartis
Institutes for Biomedical Research, 8 Novartis Pharma, 9 Royal
Free Hospital, London, United Kingdom, 10 University Hospital
Zurich, Zurich, Switzerland, 11 University of Erlangen, Erlangen,
Germany, 12 University of Florence, Firenze, Italy.
567. Comparison of Estimated Pulmonary Artery Systolic
Pressure by Echocardiography (PASPECHO) and Right Heart
Catheterization (PASPRHC) in Patients with Systemic Sclerosis
(Scleroderma, SSc). Elena Schiopu 3 , Ann J. Impens 3 , Melvyn
Rubenfire 2 , Fazleomar Mahmood 3 and Kristine Phillips 1 ,
1
University of Michigan, Ann Arbor, MI, 2 University of Michigan,
Division of Cardiology, Ann Arbor, MI, 3 University of Michigan,
Scleroderma Program, Ann Arbor, MI.
568. Determination of the Accurate Incidence of Pulmonary Arterial
Hypertension in Patients with Systemic Sclerosis, Mixed
Connective Tissue Disease and Systemic Lupus Erythematosus
by Prospective Study for 3-Years. Sumiaki Tanaka 1 , Kenta
Hoshi 4 , Junichi Tanaka 4 , Tatsuhiko Wada 4 , Toshimichi Matsui 4 ,
Tatsuo Nagai 4 , Jun Okada 2 and Shunsei Hirohata 3 , 1 Drexel
University College of MedicineDepartment of Rheumatology
and Infectious Diseases, Kitasato University School of Medicine,
Sagamihara, Kanagawa, Japan, 2 Drexel University College
of MedicineDepartment of Rheumatology and Infectious
Diseases, Kitasato University School of Medicine, Sagamihara,
Japan, 3 Drexel University College of MedicineDepartment of
Rheumatology and Infectious Diseases, Kitasato University
School of Medicine, Kanagawa, Japan, 4 Drexel University College
of MedicineDepartment of Rheumatology and Infectious
Diseases, Kitasato University School of Medicine.
569. Difficulty Using World Health Organization Criteria To
Categorize Pulmonary Hypertension in Patients with
Systemic Sclerosis. Jessica K. Gordon 3 , Mardi Gomberg-
Maitland 5 , Barbara M. Segal 2 , Robyn T. Domsic 6 , Ami A.
Shah 4 , Laura K. Hummers 4 , Virginia D. Steen 1 , Evelyn Horn 7
and PHAROS Investigators, 1 Georgetown University Medical
Center, Washington, DC, 2 Hennepin County Medical Center,
Minneapolis, MN, 3 Hospital for Special Surgery, New York,
NY, 4 Johns Hopkins University, Baltimore, MD, 5 University of
Chicago, 6 University of Pittsburgh, Pittsburgh, PA, 7 Weill-Cornell
Medical College.
570. Dyspnea in Scleroderma Patients from the PHAROS Registry:
A Major Contributor to Disability. Lorinda Chung 2 , Hubert
Chen 3 , Dinesh Khanna 5 , Ann J. Impens 4 , Virginia D. Steen 1 and
PHAROS Investigators, 1 Georgetown University Medical Center,
Washington, DC, 2 Stanford Univ Medical Center, Palo Alto,
CA, 3 UCSF, 4 Univ of Michigan Lobby M 2500, Ann Arbor, MI,
5
University of California Los Angeles, Los Angeles, CA.
186
2010 Program Book